| Symbol | BBOT |
|---|---|
| Name | BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | C/O CORMORANT ASSET MANAGEMENT, LP,200 CLARENDON STREET,52ND FLOOR, BOSTON, Massachusetts, 02116, United States |
| Telephone | 857 702 0377 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001869105 |
| Description | BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, visit bbotx.com. Additional info from NASDAQ: |
Cobo Marc 🔴 sold 125 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) at $7.80 Transaction Date: Jul 01, 2026 | Filing ID: 296504
Read moreElmelech Idan 🔴 sold 343 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) at $7.80 Transaction Date: Jul 01, 2026 | Filing ID: 296503
Read moreBen Yong 🔴 sold 1.0K shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) at $7.80 Transaction Date: Jul 01, 2026 | Filing ID: 296502
Read moreBeltran Pedro 🔴 sold 1.0K shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) at $7.80 Transaction Date: Jul 01, 2026 | Filing ID: 296501
Read moreDirector Chen Bihua 🟡 adjusted position in 0 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) Transaction Date: Jul 01, 2026 | Filing ID: 075538
Read more(99% Neutral) BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. (BBOT) Announces New Board Appointment
Read moreNew Form 424B3 - BridgeBio Oncology Therapeutics, Inc. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001193125-26-277572 <b>Size:</b> 27 KB
Read more(30% Negative) BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. (BBOT) Reports Q2 2026 Financial Results
Read moreBBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Read moreElmelech Idan 🟢 acquired 758.2K shares (1 derivative) of BridgeBio Oncology Therapeutics, Inc. (BBOT) at $7.66 ($5.8M) Transaction Date: May 10, 2026 | Filing ID: 219447
Read more